We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




New Detection Method Diagnoses Ovarian Cancer from Blood, Urine and Saliva Samples

By LabMedica International staff writers
Posted on 10 Jul 2023

Detecting ovarian cancer in its preliminary stages, when it's most effectively treatable, poses a significant challenge. More...

One potential method for identifying this cancer is through the analysis of extracellular vesicles (EVs), with a specific focus on small proteins known as exosomes that are discharged from the tumor. These proteins, being extracellular, can be gathered from body fluids such as blood, urine, and saliva. However, the practical application of these biomarkers has been hampered by a scarcity of reliable markers for ovarian cancer detection. Now, researchers have uncovered three previously undiscovered membrane proteins associated with ovarian cancer. Utilizing a novel technology of polyketone-coated nanowires, the research team successfully isolated these proteins, leading to a new detection approach for ovarian cancer detection.

The research, conducted at Nagoya University (Nagoya, Japan) involved extracting both small and medium/large EVs from high-grade serous carcinoma (HGSC), the most prevalent form of ovarian cancer. The researchers then analyzed them using liquid chromatography-mass spectrometry. Although the initial phase of the research was demanding and the validation of the identified proteins was particularly challenging, the researchers' persistent efforts paid off. After examining various antibodies, they finally identified suitable targets. The findings showed that small and medium/large EVs carry distinctly different molecules, and further study found that the small EVs make better biomarkers than their larger counterparts. The researchers identified FRα, Claudin-3, and TACSTD2 as the membrane proteins present in the small EVs connected to HGSC.

Following the successful identification of these proteins, the research team turned their attention to capturing EVs in a manner that would enable cancer detection. To achieve this, they developed polyketone chain-coated nanowires (pNWs), a technology particularly effective for extracting exosomes from blood samples. However, crafting the pNWs was not a straightforward process. The team had to experiment with multiple coatings before settling on polyketones, a completely new material for this application. Eventually, their hard work paid off as the polyketones proved to be a perfect match.

“Our findings showed that each of the three identified proteins is useful as a biomarker for HGSCs,” said Akira Yokoi of the Nagoya University Graduate School of Medicine who led the research group. “The results of this research suggest that these diagnostic biomarkers can be used as predictive markers for specific therapies. Our results allow doctors to optimize their therapeutic strategy for ovarian cancer, therefore, they may be useful for realizing personalized medicine.”

Related Links:
Nagoya University


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
New
Slide Scanner System
NanoZoomer S540MD
Platinum Member
Integrated Biochemical & Immunological System
Biolumi CX Solution X10+C10
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: iStock

Prehospital Blood Test Could Reduce Emergency Transfers for Chest Pain

Chest pain leads to ambulance transport to an emergency department for about 95% of patients, although only a minority have a serious cardiac condition. Troponin testing helps assess heart muscle damage,... Read more

Immunology

view channel
Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more

Microbiology

view channel
Image: RealTime Labs’ Mycotoxin Extensive Panel measures 31 mold-related toxins across seven toxin classes from a single urine sample (Photo courtesy of RealTime Labs)

New Urine Test Expands Mycotoxin Analysis to 31 Markers for Broader Exposure Assessment

Clinical evaluation of mold exposure increasingly relies on urinary mycotoxin testing, but limited marker coverage and metabolite masking can make results more difficult to interpret. Broader analysis... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Collaboration combines cognitive assessment, blood testing, phlebotomy, and MRI to support faster diagnosis across the UK (Image Credt: Adobe Stock)

New UK Collaboration Expands Access to Integrated Alzheimer’s Diagnostic Testing

C2N Diagnostics and Cambridge Cognition have partnered with The Alzheimer’s Trust to create an integrated pathway aimed at supporting earlier and more accurate diagnosis of Alzheimer’s disease and related dementias.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.